You are here

The Progress Report Progress never stops. Stay informed with the latest news on breast cancer research, treatment, and prevention.


HER2 x

Since 1989, breast cancer deaths have declined by 40 percent—a statistic that can be attributed in large part to advances in treatment.

chemotherapy IV against blue background

Treatment optimization–balancing efficacy with toxicity–remains a clinical challenge in early-stage breast cancer and was a major focus of clinical trials featured at this year’s virtual annual meeting of the American Society of Clinical Oncology (ASCO). Below are key highlights:


HER2-positive breast cancer represents about 25 percent of all breast cancers. Once a deadly disease with few treatment options, early stage HER2-positive breast cancer is now a treatable disease with a good prognosis for many patients.

Metastasis, when cancer cells leave the breast and spread to other sites in the body, is the major cause of mortality from breast cancer. Common sites of breast cancer metastasis are bone, lung, liver and brain.

Dr. Loi received her first BCRF research grant in 2014, but was no stranger to the BCRF researcher community.

The last full day of SABCS 2015 started with a discussion on the past and future directions of HER2- directed therapies. In his lecture, Dr.

A team of Yale researchers has discovered a new complexity in drug resistance that may lead to the development of future therapies for patients with HER2-positive breast cancer.

Large Researcher Headshot - Piccart Martine

BCRF sat down with Dr. Martine Piccart-Gebhart to discuss her current work and interest in breast cancer research. Read on to learn more.


Q: Tell us about yourself as a scientist and how you became interested in breast cancer research.